Texas

Pfizer-BioNTech seeks approval for second COVID-19 launch

NEWYou can listen to Fox News articles!

Pfizer and BioNTech asked U.S. regulators on Tuesday to approve a new booster dose of their COVID-19 vaccine for the elderly.

The organizations said Israeli data showed that people over the age of 65 would benefit from the fourth disease.

Who says there is no evidence that COVID BOOSTER is necessary for healthy children, adolescents.

The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) must approve the application.

The U.S. now expects a first record followed months later by a booster size for every 12 years or so.

Germaine T. Leftwich, 67, received a Pfizer COVID-19 shot from Drs. Tiffany Taliaferro on the security road on Capitol Hill in Washington, DC, on Monday, October 4, 2021.
(Tom Williams/CQ-Roll Call, Inc. and Getty Images)

“The protection you get from the third is enough, it’s actually very good for hospitals and deaths.” But we’re just leaving that data to the FDA and then we’ll see what happens. that’s what experts say outside of Pfizer. “

While coronavirus cases have been declining since the cold winter, with agencies and states and local governments moving to reassure those with the disease, health officials said. the world needs to be vigilant and continue to use tools to prevent disease and new diseases. .

Currently, the fourth disease is reported to be for Americans with weakened immune systems.

FAUCI said future requirements for COVID-19 promoters should be monitored.

In November 2021, the CDC increased the need for COVID-19 booster shots to all patients 18 years of age and older who received a Pfizer-BioNTech or Moderna vaccine about six months after their ingestion. second.

In a news release Tuesday, Pfizer also announced “upcoming reports” and data from Kaiser Permanente in southern California, “showing the effectiveness against COVID-19 infections. and severe illnesses relieved by omicron 3 to 6 months after receiving a first booster. (three) dose. “

While officials say it continues to offer prevention of serious diseases, they are not immune to simple diseases – many more so due to the omicron mutant.

The calls for relief came up when it became clear that the drugs were not as potent in the omicron mutant as they were against the early effects of the disease.

However, scientists now say that most Americans have the disease and that the ultimate goal is to prevent serious illness.

Click here to download the FOX NEWS program

During the omicron wave, those who received their booster two months before and 78% in the fourth month after that booster were 91% more likely to be hospitalized.

The Associated Press provided this report.

Pfizer-BioNTech seeks approval for second COVID-19 launch

Source link Pfizer-BioNTech seeks approval for second COVID-19 launch

Back to top button